108
Participants
Start Date
November 25, 2020
Primary Completion Date
July 20, 2022
Study Completion Date
July 20, 2022
Ripretinib
Oral kinase inhibitor
Sunitinib
second-line therapy in GIST patients who have progressed after imatinib treatment or are intolerant to imatinib
Beijing Cancer Hospital, Beijing
Chinese PLA General Hospital, Beijing
The General Hospital of Peking University, Beijing
The First Affiliated Hospital of Chongqing Medical Universty, Chongqing
Fujian Medical University Union Hospital, Fuzhou
The Cancer Hospital of Sun Yat-sen University, Guangzhou
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou
The sixth Affiliated hospital of Sun Yat-sen University, Guangzhou
The 4th Hospital of Hebei Medical University, Shijiazhuang
The Affiliated Hospital of Haerbin MedicalUniversity, Harbin
Union Hospital of HUST, Wuhan
The Affiliated Hospital of Qingdao University, Qingdao
Fudan University Cancer Hospital, Shanghai
Fudan University, Zhongshan Hospital, Shanghai
Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
West China Hospital of Sichuan University, Chengdu
The Affiliated Hospital of Xinjiang Medical University, Ürümqi
Zhejiang Cancer Hospital, Hangzhou
Zai Lab (Shanghai) Co., Ltd.
INDUSTRY